title: Modulation of gyrase-mediated DNA cleavage and cell killing by ATP.
abstract: An uncoupler of oxidative phosphorylation, 2,4-dinitrophenol, and an aconitase inhibitor, fluoroacetic acid, both of which are known to lower the cellular ATP pool, protected Escherichia coli cells from the bactericidal actions of gyrase poisons including quinolone antibiotics, nalidixic acid and ciprofloxacin, and the epipodophyllotoxins VP-16 and VM-26. Using purified E. coli DNA gyrase, we examined the effect of ATP on gyrase-mediated DNA cleavage in the presence of these gyrase poisons. ATP was shown to stimulate gyrase-mediated DNA cleavage from 10- to more than 100-fold in the presence of these gyrase poisons. ADP antagonized the stimulatory effect of ATP. Consequently, gyrase-mediated DNA cleavage induced by gyrase poisons is modulated by the ATP concentration/ADP concentration ([ATP]/[ADP]) ratio. Coumermycin A1, an inhibitor of the ATPase subunit of DNA gyrase, like ADP, also effectively antagonized the stimulatory effect of ATP on gyrase-mediated DNA cleavage induced by gyrase poisons. Furthermore, coumermycin A1, like DNP and fluoroacetic acid, also protected cells from the bactericidal action of gyrase poisons. In the aggregate, our results are consistent with the notion that the [ATP]/[ADP] ratio, through its modulatory effect on the gyrase-mediated DNA cleavage, is an important determinant of cellular susceptibility to gyrase poisons.
authors.affiliation: Department of Pharmacology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway 08854, USA.
authors.forename: T K
authors.initials: TK
authors.lastname: Li
authors.forename: L F
authors.initials: LF
authors.lastname: Liu
mesh_terms: D000244:Adenosine Diphosphate / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology*; D049933:Aminocoumarins; D001426:Bacterial Proteins / Q000187:drug effects* / Q000378:metabolism; D015169:Colony Count, Microbial; D003374:Coumarins / Q000494:pharmacology; D004250:DNA Topoisomerases, Type II / Q000187:drug effects* / Q000378:metabolism; D004269:DNA, Bacterial / Q000187:drug effects* / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004926:Escherichia coli / Q000187:drug effects* / Q000201:enzymology; D005463:Fluoroacetates / Q000494:pharmacology; D007641:Keratolytic Agents / Q000494:pharmacology; D011034:Podophyllotoxin / Q000494:pharmacology; D015363:Quinolones / Q000494:pharmacology; D059005:Topoisomerase II Inhibitors
chemical_list: D049933:Aminocoumarins; D001426:Bacterial Proteins; D003374:Coumarins; D004269:DNA, Bacterial; D004791:Enzyme Inhibitors; D005463:Fluoroacetates; D007641:Keratolytic Agents; D015363:Quinolones; D059005:Topoisomerase II Inhibitors; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; C014815:fluoroacetic acid; D004250:DNA Topoisomerases, Type II; D011034:Podophyllotoxin; C004628:coumermycin